Skip to main content
TipRanks
Go Ultimate75% OFF

NextPlat (NXPL) AI Stock Analysis

97 Followers
NXPL

NextPlat

(NASDAQ:NXPL)

Select Model
Rating:47Neutral
Price Target:$7.50â–²(8.54% Upside)
Action:reiterated
Date:11/20/26

The overall score of 47 reflects NextPlat's highly speculative profile, weighed heavily by substantial net losses, negative cash flows, and poor technical momentum. While poor valuation metrics and top-line revenue shrinkage are significant risks, the company's debt-free balance sheet, expanding healthcare margins, and optimistic guidance regarding recent pharmacy acquisitions provide early signs of a potential structural turnaround.

Positive Factors
Healthcare Margin ExpansionThe sharp improvement in healthcare gross margin indicates a more profitable revenue mix, particularly from contracted services. If maintained, stronger unit economics can support lower consolidated losses, improve reinvestment capacity, and make the healthcare segment a more durable earnings driver.
Negative Factors
Revenue ContractionThe recent revenue decline shows that earlier growth has not yet translated into consistent expansion. Contraction across the business can dilute operating leverage, make fixed costs harder to absorb, and increase reliance on new healthcare contracts, acquisitions, and channel initiatives to restore scale.

NextPlat (NXPL) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%40%60%NXPL+10.31%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$18.97M
Dividend Yield
―
Average Volume (3M)
26.67K
Price to Earnings (P/E)
-2.1
Beta (1Y)
0.87
Revenue Growth
-21.19%
EPS Growth
2.32%
Country
US
Employees
126
Sector
Technology
Sector Strength
61
Industry
Software - Application

NextPlat Business Overview & Revenue Model

Company Description

NextPlat Corp, along with its subsidiaries, specializes in providing advanced mobile satellite services (MSS). These offerings encompass satellite-enabled voice and data communication, comprehensive personnel and asset tracking, machine-to-machine (M...

How the Company Makes Money

NextPlat primarily makes money by selling products through e-commerce channels and earning the spread between its product revenue and the cost to source, fulfill, and market those products (i.e., retail/e-commerce gross margin). A second core revenue...

NextPlat Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:-16.65%|Next Earnings Date:May 15, 2020
Earnings Call SentimentPositive

The call was generally optimistic, with management emphasizing substantial year-over-year improvements in gross margin, operating expenses, operating loss, healthcare profitability, 340B contract growth, and global e-commerce reach. These positives outweighed ongoing challenges, including lower total and healthcare revenue, retail prescription and reimbursement pressure, the loss of a high-margin fulfillment facility, seasonal e-commerce softness, corporate overhead, cash usage, and the unresolved lawsuit.

Positive Updates

Broad Year-over-Year Operating Improvement
Management reported dramatic year-over-year improvements across nearly all key financial metrics, particularly margins and the substantial reduction in operating losses.

Negative Updates

Total Revenue Decline
Third-quarter total net revenue was $10.5 million, compared with $13.8 million in the prior-year period. Management attributed the decline to operational restructuring and evolving reimbursement dynamics within the healthcare business.

Company Guidance

NextPlat expects Scott’s Pharmacy to contribute approximately $1.2 million in quarterly revenues and $150,000 in net profits during the fourth quarter, with revenues, margins, and profitability expected to grow during 2027; the new healthcare e-commerce website is now expected to go live this month; the 14 340B contracts secured to date are expected to contribute to growth throughout the remainder of the year and through early 2027, although onboarding can take around 90 days on average before initial prescriptions are received; the Jacksonville location and Q4 acquisition of Scott’s Pharmacy are expected to improve prescription volume and customer reach, while additional e-commerce marketplaces are expected later this year.

NextPlat Financial Statement Overview

Summary

Scores a 37 due to persistent negative operating cash flows, shrinking top-line revenues, and deep unprofitability. A conservative balance sheet with minimal debt provides the primary cushion, though stockholders' equity continues to erode.

Income Statement

25Negative

Balance Sheet

55Neutral

Cash Flow

30Negative
Financial statement breakdown
BreakdownTTMMar 2026Dec 2024Mar 2024Mar 2023Dec 2021
Income Statement
Total Revenue45.04M54.32M65.48M37.76M11.71M7.74M
Gross Profit11.19M10.91M16.23M11.31M2.49M1.86M
EBITDA-6.61M-9.36M-20.15M-19.68M-6.71M-6.29M
Net Income-8.40M-11.71M-14.03M-3.78M-9.16M-8.11M
Balance Sheet
Total Assets27.15M27.46M36.48M64.47M28.64M20.57M
Cash, Cash Equivalents and Short-Term Investments11.22M13.71M19.96M26.31M18.89M17.27M
Total Debt1.61M1.49M2.26M3.01M1.07M365.22K
Total Liabilities11.31M10.04M9.68M16.38M2.87M3.03M
Stockholders Equity15.74M17.31M26.68M32.18M25.78M17.53M
Cash Flow
Free Cash Flow-2.48M-6.20M-5.65M-4.24M-4.32M-4.32M
Operating Cash Flow-2.37M-6.13M-5.46M-3.60M-3.60M-4.09M
Investing Cash Flow-113.00K163.00K-953.00K5.20M-7.72M-229.31K
Financing Cash Flow-227.00K-225.00K72.00K5.86M13.01M20.82M

NextPlat Technical Analysis

Technical Analysis SentimentNegative
Last Price6.91

Price Trends

50DMA8.59Negative
100DMA8.02Negative
200DMA6.89Positive

Market Momentum

MACD-0.41Positive
RSI38.12Neutral
STOCH48.56Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NXPL, the sentiment is Negative. The current price of 6.91 is below the 20-day moving average (MA) of 7.89, below the 50-day MA of 8.59, and above the 200-day MA of 6.89, indicating a neutral trend. The MACD of -0.41 indicates Positive momentum. The RSI at 38.12 is Neutral, neither overbought nor oversold. The STOCH value of 48.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NXPL.

NextPlat Risk Analysis

NextPlat disclosed 28 risk factors in its most recent earnings report. NextPlat reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk
1.We are currently listed on The Nasdaq Capital Market. If we are unable to maintain listing of our securities on Nasdaq or any stock exchange, our stock price could be adversely affected and the liquidity of our stock and our ability to obtain financing could be impaired and it may be more difficult for our shareholders to sell their securities.Q1, 2026

NextPlat Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

NXPL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *61Neutral$37.18B12.37-10.20%1.83%8.50%-7.62%
RYDERYDE52Neutral$181.61M-3.65-63.13%―34.88%12.77%
IPMIPM50Neutral$14.73M-6.31-20.37%―――
NXPLNXPL47Neutral$18.97M-2.13-51.01%―-21.19%2.32%
CXAICXAI44Neutral$2.67M-0.04-132.15%―27.75%29.40%
NTCLNTCL37Underperform$1.58M-0.01-228.97%―25.23%-144.16%

* Technology Sector Average

Performance Comparison

-100%0%100%200%NXPLIPMCXAIRYDEWCTNTCLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
NXPL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
NXPLNextplat Corp.6.910.9215.42%
IPMIntelligent Protection Management Corp.1.63-0.20-10.93%
CXAICxapp Inc.1.04-21.01-95.28%
RYDERyde Group Limited Class A1.070.57115.73%
WCTWellchange Holdings Company Limited2.40-595.60-99.60%
NTCLNetClass Technology Inc Class A1.73-593.77-99.71%

NextPlat Corporate Events

Business Operations and StrategyFinancial DisclosuresM&A Transactions

NextPlat Expands Rural Pharmacy Footprint in Northwest Florida

Positive
Oct 6, 2026

On October 6, 2026, NextPlat Corp completed the acquisition of a profitable independent pharmacy in a rural community near Pensacola, Florida, paying $1.49 million in cash for the business and its inventory. The pharmacy, which generated about $5.6 m...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 20, 2026